ArticleFrontiers in psychiatry2026
Genetic architecture and clinical features of Tourette syndrome in a child and adolescent cohort: an explorative clinical exome-based study.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tourette Syndrome (TS) is a neurodevelopmental disorder with a complex genetic architecture, involving both rare high-impact variants and polygenic contributions. While several risk genes have been identified by whole-exome sequencing (WES), the relationship between genetic variants and clinical phenotype in TS patients remains insufficiently characterized. Methods: We conducted an explorative clinical exome-based study in a cohort of 80 children and adolescents with TS (mean age 12.8 years; male:female = 70:10). Variants were classified as potentially causative (PC-Vs), variants of uncertain significance (VUS), or non-causative (NC-Vs) according to ACMG guidelines for variant evaluation and curated databases. Clinical assessment included tic severity through Yale Global Tic Severity Scale (YGTSS), cognitive testing, dysmorphic features, comorbid conditions, EEG and brain MRI analyses. Group comparisons were statistically performed to evaluate associations between genetic findings and phenotypic features. Results: Out of the 80 patients, 11 (13.7%) carried PC-Vs, 29 (36.3%) VUS, and 40 (50%) NC-Vs. Patients with PC-Vs exhibited significantly higher tic severity (mean YGTSS 28 ± 8.2) and lower IQ (67.6 ± 31.0) compared with VUS (YGTSS 24.2 ± 7.7; IQ 90.8 ± 23.1) and NC-Vs (YGTSS 18.5 ± 7.0; IQ 86.4 ± 20.3) (p < 0.05). Conversely, positive family history of tics was more frequent in the NC-V group (55%) than in PC-Vs (27.3%) or VUS (27.6%) (p = 0.044). Potential causative variants included Conclusion: These findings support a dual model of genetic susceptibility in TS, where rare, high-impact exomic variants may contribute to more severe tics, cognitive impairment, and syndromic presentations, whereas polygenic inheritance mostly occurs in familial and milder forms. Incorporating exome sequencing into diagnostic workflows may enhance etiological classification and inform precision-medicine strategies for TS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.